Loading company…
WeCareLife Biotech develops adiposome-based drug delivery technology for small and large molecule medicines.
Founded in 2021 and based in Beijing, China, WeCareLife Biotech's Adiposome-based Drug Delivery System is designed for small molecules, antibodies, peptides and nucleic acids. In January 2026, the company raised an undisclosed amount in Series A funding from returning investor Heda Capital. It expects to pursue IND filings and preclinical work on drug candidates.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in